What DaVita's Quarter ended Sep 30, 2026 10-Q says: 3 signals
DaVita filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses compliance burden, cybersecurity incident and product launch.
Public (DVA)Hospitals and Health Care10,000+ employeesdavita.comLinkedIn
Get DaVita's live signals in Claude or ChatGPT, or by API
What changed at DaVita this week? Use Autobound signals for davita.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 20
Source: Autobound Signal API · 32 signals tracked for DaVita · updated
10-Q · latest 10
What DaVita's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 3 signals
DaVita to Roll Out Expanded Hemodialysis Therapy to Eligible Patients in November
DaVita plans to offer expanded hemodialysis to the vast majority of its eligible patients in November, incurring supplier transition and clinical teammate training costs.
expanded hemodialysishemodiafiltration
CMS issues final ESRD PPS rule projecting 2.7% average reimbursement increase in 2027
On October 28, 2026, CMS issued a final rule updating the Medicare ESRD PPS rate and policies for calendar year 2027, projecting a 2.7% average reimbursement increase for freestanding facilities.
2.7%
projected increase in ESRD freestanding facilities' average reimbursement in 2027
DaVita incurred $25 million in remediation expenses from a 2025 network cybersecurity incident
During the second quarter of 2025, DaVita experienced a cybersecurity incident that disrupted network elements and operations, requiring remediation assistance from third-party cybersecurity professionals.
- SEC EDGAR
10-Q
Filed · 7 signals
DaVita closes strategic acquisition of interest in home healthcare provider Elara Caring.
DaVita completed its acquisition of a minority interest in Elara Caring on July 20, 2026, signaling a strategic expansion into the home healthcare market.
Elara CaringChange HealthcareUnitedHealth GroupJPMorgan Chase Bank, N.A.
DaVita secured a new $500M term loan and amended its credit facility in June 2026.
The company incurred a new $500 million Term Loan B-2 and executed the Ninth Amendment to its credit agreement with JPMorgan Chase Bank.
$500M
Principal amount of new incremental Term Loan B-2 tranche
JPMorgan Chase Bank, N.A.
DaVita's cash flow is pressured by rising DSO and prior cybersecurity disruption.
The company's Days Sales Outstanding (DSO) increased from 49 to 52 days, tying up cash in its $1.719 billion receivables.
$1.7B
U.S. dialysis accounts receivable balance
UnitedHealth GroupChange Healthcare
Recovering from collection disruptions caused by Change Healthcare cybersecurity incident.
The company's cash flow was negatively impacted in the prior year by a cybersecurity incident at its partner, Change Healthcare, requiring a $93 million repayment of interest-free funding.
$93M
repayment of interest-free funding related to cybersecurity incident
UnitedHealth GroupChange HealthcareJPMorgan Chase Bank, N.A.
U.S. dialysis Days Sales Outstanding (DSO) increased to 52 days, indicating collection issues.
The company's U.S. dialysis DSO increased from 49 to 52 days, with accounts receivable growing to $1.719 billion.
$1.7B
U.S. dialysis accounts receivable balance
Allocated portion of $197M in H1 2026 maintenance CapEx for IT investments.
The company confirmed that its $197 million in maintenance capital expenditures for the first half of 2026 includes dedicated spending for 'investments in information technology'.
$197M
Total maintenance capital expenditures for H1 2026, which includes IT investments
information technology
DaVita purchased renewable energy credits in Q2 2026 as part of its tax strategy.
Earlier 10-Q filings
- 10-QFiled · 10 signalsSEC EDGAR
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
DaVita earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Launching long-term investments to replace scheduling and upgrade revenue operations tech.The company is actively replacing its scheduling system and upgrading its revenue operations technology as part of a long-term IT infrastructure investment. This creates a significant opportunity for vendors specializing in healthcare scheduling and Revenue Cycle Management (RCM) platforms. | |
| Investing in long-term replacement of core scheduling and revenue operations systems.The company is actively making long-term investments to replace its scheduling system and upgrade its revenue operations technology, presenting a clear opportunity for enterprise software vendors in these domains. | |
| Experiencing negative business impact from a recent cyber incident.A recent cyber incident caused lost patient admissions, negatively impacted revenue per treatment, and slowed down revenue cycle operations. This event creates a strong impetus for reviewing and investing in cybersecurity, business continuity, and operational resilience solutions. | |
| Committing to long-term IT and clinical innovation to create sustainable value.The CEO framed technology and clinical innovation not as one-off projects, but as a long-term strategic commitment to strengthen the company's capabilities. This indicates a durable spending environment for vendors who can align with their goals of superior patient care and sustainable value. | |
| Investing in data science and research to advance kidney care therapies.The company highlighted its DaVita Clinical Research (DCR) division, which leverages one of the largest patient data sources in the country. This focus on data-driven research and development signals a need for data science, analytics, and clinical trial support technologies. | |
| Deployed $1.5 billion in share repurchases year-to-date, showing strong capital position.The company has spent $1.5 billion on share buybacks this year, demonstrating significant financial strength and available capital. While not direct operational spending, it indicates a healthy balance sheet and the capacity to fund major strategic investments. |
Signal API · MCP
Track DaVita with the Signal API
One POST /v1/companies/enrich call with davita.com returns DaVita 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"davita.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about DaVita 10-Q
When did DaVita file its latest 10-Q?
What did DaVita disclose in its latest 10-Q?
What did DaVita say on its recent earnings calls?
Where can I read DaVita's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .